Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

PHIO

Phio Pharmaceuticals Corp

Apr 23 • 04:00PM ET

0.7000

Dollar change -0.1299
Percentage change -15.65	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-6.27	Insider Own	1.54%	Shs Outstand	4.59M	Perf Week	7.00%
Market Cap	3.21M	Forward P/E	-	EPS next Y	-	Insider Trans	3.67%	Shs Float	4.52M	Perf Month	-3.43%
Income	-10.83M	PEG	-	EPS next Q	-	Inst Own	11.04%	Short Float	0.47%	Perf Quarter	2.94%
Sales	0.00M	P/S	-	EPS this Y	31.54%	Inst Trans	-17.29%	Short Ratio	0.05	Perf Half Y	-49.64%
Book/sh	2.06	P/B	0.34	EPS next Y	-	ROA	-97.63%	Short Interest	0.02M	Perf Year	-81.82%
Cash/sh	1.85	P/C	0.38	EPS next 5Y	-	ROE	-116.60%	52W Range	0.50 - 6.85	Perf YTD	-7.89%
Dividend Est.	-	P/FCF	-	EPS past 5Y	62.38%	ROI	-140.05%	52W High	-89.78%	Beta	1.29
Dividend TTM	-	Quick Ratio	5.71	Sales past 5Y	-36.96%	Gross Margin	-	52W Low	40.00%	ATR (14)	0.10
Dividend Ex-Date	-	Current Ratio	5.71	EPS Y/Y TTM	37.88%	Oper. Margin	0.00%	RSI (14)	47.32	Volatility	22.90% 10.90%
Employees	9	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	4.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	78.91%	Payout	-	Rel Volume	1.48	Prev Close	0.83
Sales Surprise	-	EPS Surprise	143.08%	Sales Q/Q	-	Earnings	Apr 02 BMO	Avg Volume	433.53K	Price	0.70
SMA20	1.33%	SMA50	-12.09%	SMA200	-47.34%	Trades		Volume	642,541	Change	-15.65%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-05-20	Initiated	H.C. Wainwright	Buy	$4

Apr-22-24 01:10PM	Intratumoral Injection of Phio's PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells (GlobeNewswire) +29.69%
Apr-16-24 07:30AM	Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID) (GlobeNewswire)
Apr-11-24 07:30AM	Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT) (GlobeNewswire)
Apr-03-24 07:30AM	National Spotlight Features Phio's Innovative RNAi Technology Platform (GlobeNewswire)
Apr-02-24 07:30AM	Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update (GlobeNewswire)
07:30AM	Loading…
Mar-21-24 07:30AM	Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies (GlobeNewswire) -21.50%
Mar-13-24 02:00PM	Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research (GlobeNewswire)
Mar-06-24 10:30AM	Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin Disorders (GlobeNewswire) +6.63%
Jan-31-24 08:00AM	Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies (GlobeNewswire)
Dec-07-23 08:00AM	Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceeds (GlobeNewswire) -42.14%
Nov-09-23 04:30PM	Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -10.53%
07:30AM	Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas (GlobeNewswire)
Nov-03-23 12:00PM	Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor Control (GlobeNewswire) +6.57%
Oct-12-23 11:00AM	Phio Pharmaceuticals Announces Upcoming Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (GlobeNewswire) -32.31%
Oct-11-23 07:30AM	Phio Pharmaceuticals Presents New Data for Targeting of BRD4 with its INTASYL Compound PH-894 (GlobeNewswire) +87.05%
07:30AM	Loading…
Sep-06-23 07:30AM	Phio CEO to Speak at Wainwright Conference in New York in September (GlobeNewswire)
Aug-21-23 07:30AM	Phio Pharmaceuticals Announces Dosing of First Patient in Collaborative Clinical Trial with AgonOx, Inc. and Providence Cancer Institute (GlobeNewswire)
Aug-10-23 04:30PM	Phio Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jun-02-23 01:30PM	Phio Pharmaceuticals Announces Closing of $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules (PR Newswire)
May-31-23 08:00AM	Phio Pharmaceuticals Announces $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules (PR Newswire) -13.15%
May-24-23 07:30AM	Phio Pharmaceuticals Announces Initiation of Collaborative Clinical Trial with PH-762, AgonOx's Tumor Infiltrating Lymphocyte Program (AGX148) and Providence Cancer Institute (PR Newswire)
May-18-23 12:00PM	Phio Pharmaceuticals Presents Preclinical Study Showing INTASYL Treatment of NK Cells More than Doubles Ability to Kill Tumor Cells (PR Newswire) +34.31%
May-16-23 07:30AM	Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas (PR Newswire) +21.36%
May-11-23 05:00PM	Phio Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
Apr-20-23 02:20PM	Phio Pharmaceuticals Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (PR Newswire)
Apr-18-23 12:10PM	Phio Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (PR Newswire) -19.24%
07:30AM	Phio Pharmaceuticals Presents Preclinical Data Demonstrating Synergy-Enhanced in vivo Anti-Tumor Efficacy of PD-1/CTLA-4 Dual-Targeting INTASYL (PR Newswire)
Apr-17-23 07:30AM	Phio Pharmaceuticals Presents Preclinical Study Showing PH-762 Induces Systemic Memory T Cell Mediators of Anti-Tumor Immunity (PR Newswire) +18.48%
Mar-22-23 05:05PM	Phio Pharmaceuticals Reports 2022 Year End Financial Results and Provides Business Update (PR Newswire)
Feb-22-23 07:30AM	Phio Pharmaceuticals Appoints Robert Bitterman as President and Chief Executive Officer (PR Newswire)
07:30AM	Loading…
Feb-13-23 07:30AM	Phio Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements (PR Newswire)
Feb-10-23 07:30AM	Phio Pharmaceuticals Announces Positive DMC Recommendation and Continued Enrollment of Advanced Melanoma Study Without Modification (PR Newswire) -11.68%
Jan-25-23 08:30AM	Phio Pharmaceuticals Announces Reverse Stock Split (PR Newswire) -6.45%
Jan-06-23 04:30PM	Phio Showcases Innovations in Dermatology Cancers at 2023 Dermatology Summit in San Francisco (PR Newswire) +40.26%
01:30PM	Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial With PH-762 and AgonOx's Tumor Infiltrating Lymphocytes (AGX148) to Treat Solid Tumors (PR Newswire)
Dec-21-22 04:15PM	Phio Pharmaceuticals Announces New Clinical Program to Study PH-762 for the Treatment of Cutaneous Squamous Cell Carcinoma (PR Newswire)
Nov-10-22 06:25PM	Phio Pharmaceuticals Corp. (PHIO) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -7.13%
05:05PM	Phio Announces New Appointments to Leadership Team, Reports on Third Quarter 2022 Financial Results and Provides Business Update (PR Newswire)
09:00AM	Phio Pharmaceuticals Announces Study Results at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 10th and 11th (PR Newswire)
Oct-25-22 12:00PM	What Makes Phio Pharmaceuticals Corp. (PHIO) a New Buy Stock (Zacks)
Oct-12-22 09:38AM	Corcept (CORT) Begins Phase II Study on Dazucorilant for ALS (Zacks) +9.19%
Oct-07-22 05:42PM	Encompass Health (EHC), Piedmont Tie Up to Better Serve Georgia (Zacks)
Oct-06-22 07:30AM	Phio Pharmaceuticals Announces Upcoming Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (PR Newswire)
Sep-29-22 08:30AM	Phio Pharmaceuticals Announces Appointment of Robert Bitterman as Executive Chairman (PR Newswire) -5.20%
Sep-27-22 03:51PM	Encompass Health (EHC) Plans Hospital to Aid Florida Footprint (Zacks)
Sep-26-22 12:09PM	Spectrum (SPPI) Down as FDA Panel Votes Against NSCLC Drug (Zacks)
Sep-22-22 07:30AM	Phio Pharmaceuticals Announces Preclinical Data Demonstrating PH-762 Enhances Persistence of T cells for Tumor Cell Killing as Presented by Helmholtz Munich at the 9th Immunotherapy of Cancer Conference (PR Newswire)
Sep-12-22 07:30AM	Phio Pharmaceuticals Announces Acceptance of Six Abstracts at The 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (PR Newswire)
Aug-11-22 05:00PM	Phio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update (PR Newswire)
Jul-11-22 06:53AM	Phio Pharmaceuticals Corp. (NASDAQ:PHIO) Is About To Turn The Corner (Simply Wall St.)
Jun-06-22 02:15PM	Phio Pharmaceuticals Presents Study Outline of Its First Clinical Trial with PH-762 for Advanced Melanoma at the 2022 ASCO Annual Meeting (PR Newswire)
May-16-22 12:22PM	Phio Pharma's New Preclinical Data Shows PH-894 Enhances Activity of Cancer CAR-T Cells (Benzinga)
08:00AM	Phio Pharmaceuticals Presents New Data Demonstrating PH-894 Enhances Activity of HER2-CAR-T Cells at ASGCT 2022 (PR Newswire)
May-12-22 04:50PM	Phio Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update (PR Newswire)
May-05-22 08:33AM	Phio Pharmaceuticals Announces Senior Leadership Personnel Change (PR Newswire)
May-03-22 07:30AM	Phio Pharmaceuticals Announces Trial-In-Progress Poster at ASCO 2022 (PR Newswire)
May-02-22 04:30PM	Phio Pharmaceuticals Announces Upcoming Presentation of PH-894 Data at ASGCT 25th Annual Meeting 2022 (PR Newswire)
07:30AM	Phio Pharmaceuticals Announces the Appointment of Patricia A. Bradford to its Board of Directors (PR Newswire)
Apr-26-22 10:15AM	Phio Pharmaceuticals Announces the Start of its Phase 1b Clinical Trial of PH-762 for the Treatment of Advanced Melanoma (PR Newswire) -8.77%
Apr-18-22 09:30AM	Phio Pharmaceuticals Selected to Present at the Tumor Immune Microenvironment Workshop of the Society for Immunotherapy of Cancer (PR Newswire)
Apr-11-22 03:39PM	We're Keeping An Eye On Phio Pharmaceuticals' (NASDAQ:PHIO) Cash Burn Rate (Simply Wall St.) -25.53%
10:41AM	Healthcare Breakthroughs: Veru, Nova Mentis, Phio, and PharmaDrug; Visionary CEOs Report Latest Advances in New Drug Development for COVID-19, Cancers, Glaucoma, and Autism (GlobeNewswire)
Apr-08-22 01:00PM	Phio Pharmaceuticals Presents Positive New Data on PH-894 Demonstrating Antitumor Efficacy in Model of PD-1 Refractory Disease at the AACR Annual Meeting 2022 (PR Newswire) +159.18%
Mar-22-22 05:00PM	Phio Pharmaceuticals Reports 2021 Year End Financial Results and Provides Business Update (PR Newswire)
Mar-08-22 04:30PM	Phio Pharmaceuticals Announces Upcoming Presentation of PH-894 Data at the AACR Annual Meeting 2022 (PR Newswire) +5.71%
Feb-22-22 09:30AM	Phio Pharmaceuticals Initiates In Vivo Studies of INTASYL Based Antivirals Against SARS-CoV-2 (PR Newswire)
Jan-11-22 12:30PM	3 Hot Penny Stocks: Why TLOFF, PHIO and SBEV Are Seeing Big Gains Today (InvestorPlace) +8.41%
07:30AM	Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial for PH-762 to Treat Melanoma (PR Newswire)
Jan-03-22 07:30AM	Phio Pharmaceuticals Scheduled to Participate in the H.C. Wainwright Virtual BioConnect 2022 Conference (PR Newswire) +9.00%
Dec-06-21 09:28AM	Analysts Expect Breakeven For Phio Pharmaceuticals Corp. (NASDAQ:PHIO) Before Long (Simply Wall St.) +5.08%
Nov-12-21 07:00AM	Phio Pharmaceuticals Presents Positive New Data On Systemic Immune Response After Local PH-762 Therapy at the SITC 36th Annual Meeting (PR Newswire)
Nov-10-21 04:40PM	Phio Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update (PR Newswire)
Oct-18-21 07:05AM	Phio Pharmaceuticals Announces Upcoming Presentation at the SITC 36th Annual Meeting (PR Newswire)
Oct-07-21 09:00AM	Phio Pharmaceuticals Presents New BRD4 Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (PR Newswire)
Sep-30-21 08:05AM	Phio Pharmaceuticals Announces Two Upcoming Data Presentations at Scientific Conferences in October 2021 (PR Newswire)
Sep-16-21 12:12PM	38 Stocks Moving In Thursday's Mid-Day Session (Benzinga) +10.66%
08:08AM	Phio Pharma Shares Are Moving Higher On INTASYL Preclinical Data At ESMO Presentation (Benzinga)
07:40AM	20 Stocks Moving in Thursday's Pre-Market Session (Benzinga)
07:05AM	Phio Pharmaceuticals Presents Data at ESMO 2021 Demonstrating Persistent Anti-Tumor Immunity with INTASYL Dual-Targeting PD-1 and BRD4 (PR Newswire)
Sep-03-21 07:05AM	Phio Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference September 13th-15th (PR Newswire)
Aug-31-21 08:05AM	Phio Pharmaceuticals Announces Upcoming Data Presentation at the ESMO Virtual Congress 2021 (PR Newswire) +8.33%
Aug-12-21 05:00PM	Phio Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update (PR Newswire)
Jul-07-21 04:30PM	Phio Pharmaceuticals Scheduled to Participate in a Fireside Chat with H.C. Wainwright on July 12th (PR Newswire)
Jun-22-21 11:04AM	Phio Pharmaceuticals Reschedules Fireside Chat Hosted by H.C. Wainwright for July 12th (PR Newswire)
Jun-14-21 04:09PM	Is Phio Pharmaceuticals Corp. (PHIO) A Good Stock To Buy? (Insider Monkey) +9.05%
08:00AM	Phio Pharmaceuticals Scheduled to Participate in Two Upcoming Investor Events in June (PR Newswire)
Jun-04-21 08:00AM	Phio Pharmaceuticals Presents New In Vivo Data at the 2021 ASCO Annual Meeting Showing Dual-Targeting INTASYL Offers Increased Efficacy and Safety Potential Over Other Therapeutic Approaches (PR Newswire)
May-13-21 05:00PM	Phio Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update (PR Newswire) -8.78%
May-11-21 01:10PM	Phio Pharma's PH-762 Shows Encouraging Antitumor Efficacy In Preclinical Studies (Benzinga) -14.12%
08:00AM	Phio Pharmaceuticals Presents Positive In Vivo Data at ASGCT Showing PH-762 Significantly Enhanced Antitumor Efficacy of HER2-Targeted CAR-T Cells (PR Newswire)
Apr-29-21 07:30AM	Phio Pharmaceuticals Announces Upcoming Data Presentations at the ASGCT and ASCO Annual Meetings (PR Newswire)
Apr-12-21 07:33AM	Phio Pharma's Intasyl Platform Shows Promising Tumor Control Activity In Animal Studies (Benzinga) -10.95%
Apr-10-21 08:30AM	Phio Pharmaceuticals Presents Positive In Vivo Data Showing Strong Tumor Control for the Intratumoral Delivery of INTASYL RNAi Targeting PD-1 (PR Newswire)
Mar-25-21 05:15PM	Phio Pharmaceuticals Reports 2020 Year End Financial Results and Provides Business Update (PR Newswire)
Mar-11-21 07:30AM	Phio Pharmaceuticals To Present New Data on PD-1 Targeting INTASYL at the 2021 American Association for Cancer Research (AACR) Annual Meeting (PR Newswire) +10.92%
Mar-01-21 08:00AM	Phio Pharmaceuticals and AgonOx, Inc. Announce Collaboration on Clinical Development of Novel T Cell-based Cancer Immunotherapies (PR Newswire) +7.69%
Feb-17-21 04:15PM	Phio Pharmaceuticals Announces Closing of $7.7 Million Registered Direct Offering of Common Stock Priced At-the-Market (PR Newswire) +7.57%
Feb-12-21 07:00AM	Phio Pharmaceuticals Announces $7.7 Million Registered Direct Offering of Common Stock Priced At-the-Market (PR Newswire)
Jan-25-21 05:14PM	Phio Pharmaceuticals Announces Closing of $14.0 Million Private Placement Priced At-the-Market (PR Newswire)
Jan-21-21 03:33PM	Phio Pharmaceuticals Announces $14.0 Million Private Placement Priced At-the-Market (PR Newswire) -8.77%

Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bitterman Robert J	President & CEO	Feb 26 '24	Buy	0.91	2,500	2,275	18,990	Feb 27 04:42 PM
Bitterman Robert J	President & CEO	Jul 01 '23	Buy	2.84	1,000	2,840	19,211	Jul 05 06:00 PM
Bitterman Robert J	President & CEO	Jun 30 '23	Buy	2.88	1,000	2,880	18,211	Jul 05 06:00 PM
Ferrara Robert L	Director	Jun 14 '23	Buy	3.10	2,000	6,200	6,000	Jun 15 05:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PHIO

Phio Pharmaceuticals Corp

Upgrade your FINVIZ experience